Charnaia M.A.; Dement'eva I.I.; Morozov Iu.A.; Gladysheva V.G.; Isaeva A.M.

doi:https://doi.org/

Charnaia M.A.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Dement'eva I.I.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Morozov Iu.A.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Gladysheva V.G.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

ORCID: 0000-0002-3703-0911

Isaeva A.M.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Authors:

Charnaia M.A., Dement'eva I.I., Morozov Iu.A., Gladysheva V.G., Isaeva A.M.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(2): 87‑91

Read: 1719 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Charnaia MA, Dement'eva II, Morozov IuA, Gladysheva VG, Isaeva AM. . Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(2):87‑91. (In Russ.)

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

References:

Barkagan Z.S. Klinicheskoe znachenie i problemy lecheniya bol'nykh s indutsirovannoi geparinom trombotsitopeniei. Ter arkh 1999; 7: 72-76.
Barkagan Z.S. O primenenii fraksiparina dlya profilaktiki i lecheniya tromboembolii u bol'nykh s indutsiruemoi geparinom trombotsitopeniei. Ter arkh 1993; 10: 77-82.
Charnaya M.A., Dement'eva I.I., Morozov Yu.A. Geparin-indutsirovannaya trombotsitopeniya: etiologiya, patogenez, diagnostika, vedenie bol'nykh. Germany, Saarbrücken:
Charnaya M.A., Morozov Yu.A. Trombozy v klinicheskoi praktike. M: GEOTAR-Media 2009; 224.
Babuin L., Pengo V. Argatroban in the management of heparin-induced thrombocytopenia. Vasc Health Risk Manag 2010; 6: 813-819.
Beiderlinden M., Treschan T.A., Gorlinger K., Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007; 41: 749-754.
Burch M., Cooper B. Fondaparinux-associated heparin-induced thrombocytopenia. Proc Bayl Univ Med Cent 2012; 25: 1: 13-15.
Chong B.H. Heparin-induced thrombocytopenia. Br J Haematol 1995; 89: 431-439.
Chuter T.A., Pak L.K., Gordon R.L. et al. Heparin-induced thrombocytopenia and graft thrombosis following endovascular aneurysm repair. J Endovasc Ther 2003; 10: Suppl 6: 1087-1090.
Edson J.R. Heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120: 355-356.
Farner B., Eichler P., Kroll H., Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85: 6: 950-957.
Gambaro G., Baggio B. Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol Dial Transplant 1996; 11: 762-764.
Gonault-Heilmann M., Huet Y., Adhot S. et al. Low molecular weight heparin fractions as an alternative therapy in heparin-induced thrombocytopenia. Haemostasis 1987; 17: 134-140.
Greinacher A. The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost 2004; 30: 3: 315-327.
Jaben E.A., Torloni A.S., Prutni R.K., Winters J.L. Use of plasma exchange in patients with heparin-induced thrombocytopenia: a report of two cases and a review of the literature. J Clin Apher 2011; 26: 4: 219-224.
Kajitani M., Aguinaga M., Johnson C.E. et al. Use of plasma exchange and heparin during cardiopulmonary bypass for a patient with heparin induced thrombocytopenia: a case report. J Card Surg 2001; 16: 313-318.
Kramera R., Oberg-Higgins P., Russoa L., Braxton J.H. Heparin-induced thrombocytopenia with thrombosis syndrome managed with plasmapheresis. Interact Cardio Vasc Thorac Surg 2009; 8: 4: 439-441.
Leroy J., Leclerc M.H., Delahousse B. et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin Thromb Haemost 1985; 11: 326-329.
Lewis B.E., Wallis D.E., Leya F. et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Int Med 2003; 163: 1849-1856.
Magnani H.N. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554-561.
Pistulli R., Oberle V., Figulla H.R. et al. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia. Blood 2011; 22: 1: 76-78.
Poullin P., Pietri P.A., Lefevre P. Heparin-induced thrombocytopenia with thrombosis: successful treatment with plasma exchange. Br J Haematol 1998; 102: 630-631.
Robinson J.A., Lewis B.E. Plasmapheresis in the management of heparin-induced thrombocytopenia. Semin Hematol 1999; 36: 29-32.
Schiele F., Vuiltemouot A., Kramarz P. et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Haematol 1995; 50: 20-25.
Tarasova N.L., Barkagan Z.S., Kotowshikova E.F. International Society of Haematology. Meeting, 13-th. Istambul 1995; 671.
Tsu L.V., Dager W.E. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia. Ann Pharmacother 2011; 45: 10: 1185-1192.
von Segesser L.K., Mueller X., Marty B. et al. Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass. Perfusion 2002; 17: 2: 411-416.
Warkentin T.E. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996; 10: 4: 249-258.
Warkentin T.E. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Saf 1997; 17: 5: 325-341.
Warkentin T.E. Think of HIT. Hematoly Am Soc Hematol Educ Program 2006; 408-414.
Warkentin T.E., Cook R.J., Marder V.J. et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 12: 3791-3796.
Warkentin T.E., Greinacher A., Koster A., Lincoff A.M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th editor). Chest 2008; 133: 340S -380S.
Warkentin T.E., Levine M.N., Hirsh J. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
Welsby I.J., Um J., Milano C. et al. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 2010; 110: 30-35.
Zoldhelyi P., Webster M.W., Fuster V. et al. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993; 88: 5: 2015-2022.